Concomitant chemotherapy and IFN-alpha for small cell lung cancer: a randomized multicenter phase III study
1999 (English)In: Journal of Interferon and Cytokine Research, ISSN 1079-9907, Vol. 19, no 3, 253-9 p.Article in journal (Refereed) Published
Patients with any stage of small cell lung cancer were given low-dose interferon-alpha (IFN-alpha) from the first day of treatment as long as possible irrespective of changes in treatment dictated by disease progression. All patients received 6 cycles of the chemotherapy (CT): cisplatin 70 mg/m2 i.v. day 1 and etoposide 100 mg/m2 i.v. days 1, 2, 3 every 28 days. Seventy-eight patients were assigned to arm 1: CT alone, 75 patients to arm 2: CT + natural IFN-alpha (3 MU three times a week i.m.), and 66 patients to arm 3: CT + recombinant IFN alpha-2a (3 MU three times a week i.m.). There was no difference in median survival between the arms (10.2 months, 10.0 months, 10.1 months, respectively), p = 0.32. The 2-year survival rates were 15%, 3%, and 11%, respectively. Grade 3 and 4 leukopenia occurred more frequently in the IFN arms than in the CT alone arm and resulted in dose reductions. Antibodies occasionally developed to recombinant IFN. We conclude that IFN-alpha can be administered concomitantly with chemotherapy but is probably better kept for maintenance therapy so that optimal full doses of induction CT can be given.
Place, publisher, year, edition, pages
1999. Vol. 19, no 3, 253-9 p.
Medical and Health Sciences
IdentifiersURN: urn:nbn:se:uu:diva-55890DOI: 10.1089/107999099314180PubMedID: 10213464OAI: oai:DiVA.org:uu-55890DiVA: diva2:83798